Bristol Myers Squibb (CELG-RI) Non-Current Assets (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Non-Current Assets data on file, last reported at $59.3 billion in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $59.3 billion, down 3.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $242.6 billion (down 5.89% YoY), and the FY2025 annual result was $60.6 billion, down 3.46% from the prior year.
• Non-Current Assets retreated to $59.3 billion in Q1 2026 per CELG-RI's latest filing, from $60.6 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $72.9 billion in Q1 2022 and troughed at $59.3 billion in Q1 2026.
• A 5-year average of $65.6 billion and a median of $65.4 billion in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets slipped 14.55% in 2022, then increased 4.71% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $69.5 billion in 2022, then declined by 8.85% to $63.4 billion in 2023, then declined by 0.89% to $62.8 billion in 2024, then declined by 3.46% to $60.6 billion in 2025, then decreased by 2.28% to $59.3 billion in 2026.
• Business Quant data shows CELG-RI's Non-Current Assets at $59.3 billion in Q1 2026, $60.6 billion in Q4 2025, and $61.3 billion in Q3 2025.